BIO

2.26%

68.0¢ biome australia limited

agree SFcholesterol probiotic launch to the open market in the...

First 45 Last

Share
Profile

Follow
Kyriaco

1,614 Posts.

732

15/02/24

14:06

Post #: 72424435
Share
Originally posted by seaforth1: ↑

K Man

Totally agree - I have actually started to think about BIO's prospects in even more simple terms as follows

I suspect BIO will exceed their revised forecast of $12.5 million for 23/24 and reckon it could well be closer to $13.5 - $14 million

A very much back of the envelope approach to my thinking is as follows

Assume $13.5 million for 23/24 - that would be an amazing and circa 90% growth on last years (from memory) $7.2 million in sales.

Take a conservative view and as such assume a diminishing annual sales growth rate and drop 90% back to say 70% for 24/25 - $13.5 sales grows to $23 million

Drop growth rate again for 25/26 to say 55% - $23 sales grows to $36 million

Drop growth again for 26/27 to say 40% - $36 sales becomes $51 million

Drop growth again for 27/28 to say 30% - $51 sales becomes $67 million

So even with a falling annual growth BIO is selling/growing like crazy

The exciting prospect therefore is where this company might be in terms of $$ sales if they maintain high growth levels - simply put if growth diminishes at a slower pace than the examples above.

A hugely exciting few years ahead if BIO keeps executing strategy as they have to date, keep developing great products and keep expanding sales networks both here and overseas - for example the UK market has 76 million people and is 3 times the size of the Australian market - what do things look like if that really grabs and or they start accelerating into European and Asian markets and so on.

It is the compounding potential of annualised % growth to sales volume that is so exciting for mine.

People can play with the annualised % growth numbers above and you will see what I mean

Very happy to be long in this one and holding onto every share I have

DYOR and good luck to all holders

Expand

agree SF

cholesterol probiotic launch to the open market in the next few months is going to be really exciting - I expect huge interest and demand for this product !
BIO Price at posting: 30.5¢ Sentiment: Buy Disclosure: Held
5 Upvote

0 Great analysis

Reply

Top Stories

CKA

Cokal upgrades infrastructure for BBM ramp-up in Indonesia

SLS

Solstice Minerals to ramp up drilling campaign at Yarri Gold Project

BUX

Buxton projects new graphite province discovery at WA Narryer play

Week 40 Wrap: China's nonsensical stimmy hype wanes (shocking!); HotCopper's picks; oil & inflation

BCI

BCI reaches close of funding facility for salt-first part of Mardie project

ACW

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

RCE

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

WCN

White Cliff jumps 24% on 'bonanza grade' copper rock chips at Rae project, Canada

NTI

Neurotech knocked back by FDA as agency declares target condition not rare enough for special status

COD

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

There are more pages in this discussion • 16 more messages in this thread...

First 45 Last

Add BIO (ASX) to my watchlist

(20min delay)
Last 68.0¢		Change 0.015(2.26%)		Mkt cap ! $149.0M

Open	High	Low	Value	Volume
66.5¢	69.0¢	66.0¢	$173.2K	255.3K

Buyers (Bids)

No.	Vol.	Price($)
3	46226	68.0¢

Sellers (Offers)

Price($)	Vol.	No.
69.0¢	83602	3

View Market Depth

No.	Vol.	Price($)
1	44195	0.680
1	1000	0.670
8	41745	0.660
1	16550	0.655
5	27476	0.650

Price($)	Vol.	No.
0.690	48000	2
0.700	11170	2
0.705	5839	1
0.720	44230	3
0.735	18000	1

Last trade - 16.10pm 04/10/2024 (20 minute delay)

BIO (ASX) Chart

agree SFcholesterol probiotic launch to the open market in the...

Cokal upgrades infrastructure for BBM ramp-up in Indonesia

Solstice Minerals to ramp up drilling campaign at Yarri Gold Project

Buxton projects new graphite province discovery at WA Narryer play

Week 40 Wrap: China's nonsensical stimmy hype wanes (shocking!); HotCopper's picks; oil & inflation

BCI reaches close of funding facility for salt-first part of Mardie project

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

White Cliff jumps 24% on 'bonanza grade' copper rock chips at Rae project, Canada

Neurotech knocked back by FDA as agency declares target condition not rare enough for special status

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

agree SFcholesterol probiotic launch to the open market in the...

Top Stories

Cokal upgrades infrastructure for BBM ramp-up in Indonesia

Solstice Minerals to ramp up drilling campaign at Yarri Gold Project

Buxton projects new graphite province discovery at WA Narryer play

Week 40 Wrap: China's nonsensical stimmy hype wanes (shocking!); HotCopper's picks; oil & inflation

BCI reaches close of funding facility for salt-first part of Mardie project

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

White Cliff jumps 24% on 'bonanza grade' copper rock chips at Rae project, Canada

Neurotech knocked back by FDA as agency declares target condition not rare enough for special status

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News